Ameriprise Financial Inc Cytokinetics Inc Transaction History

Ameriprise Financial Inc

$381 Billion
Q3 2024

A detailed history of Ameriprise Financial Inc transactions in Cytokinetics Inc stock. As of the latest transaction made, Ameriprise Financial Inc holds 542,135 shares of CYTK stock, worth $29.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

542,135

Previous 344,134 57.54%

Holding current value

$29.7 Million

Previous $18.6 Million 53.52%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$51.22 - $60.16 $10.1 Million - $11.9 Million	198,001 Added 57.54%	542,135 $28.6 Million
Q2 2024 Aug 14, 2024	BUY	$47.86 - $75.05 $2.4 Million - $3.76 Million	50,111 Added 17.04%	344,134 $18.6 Million
Q1 2024 May 15, 2024	SELL	$63.75 - $108.06 $2.76 Million - $4.67 Million	-43,232 Reduced 12.82%	294,023 $20.6 Million
Q4 2023 Feb 14, 2024	BUY	$26.88 - $83.49 $586,978 - $1.82 Million	21,837 Added 6.92%	337,255 $28.2 Million
Q3 2023 Nov 14, 2023	SELL	$29.46 - $36.61 $873,489 - $1.09 Million	-29,650 Reduced 8.59%	315,418 $9.29 Million
Q2 2023 Aug 14, 2023	SELL	$32.62 - $40.75 $1.83 Million - $2.29 Million	-56,086 Reduced 13.98%	345,068 $11.3 Million
Q1 2023 May 15, 2023	SELL	$33.36 - $45.71 $541,699 - $742,238	-16,238 Reduced 3.89%	401,154 $14.1 Million
Q4 2022 Feb 14, 2023	SELL	$35.77 - $51.11 $4.49 Million - $6.41 Million	-125,504 Reduced 23.12%	417,392 $19.1 Million
Q3 2022 Nov 14, 2022	SELL	$38.54 - $54.52 $710,908 - $1.01 Million	-18,446 Reduced 3.29%	542,896 $26.3 Million
Q2 2022 Aug 15, 2022	BUY	$33.93 - $48.92 $80,481 - $116,038	2,372 Added 0.42%	561,342 $22.1 Million
Q1 2022 May 16, 2022	SELL	$29.74 - $46.0 $18,200 - $28,152	-612 Reduced 0.11%	558,970 $20.6 Million
Q4 2021 Feb 14, 2022	BUY	$34.35 - $46.38 $7.08 Million - $9.56 Million	206,147 Added 58.33%	559,582 $25.5 Million
Q3 2021 Nov 15, 2021	BUY	$18.54 - $35.74 $712,177 - $1.37 Million	38,413 Added 12.19%	353,435 $12.6 Million
Q2 2021 Aug 16, 2021	SELL	$19.79 - $26.99 $19,928 - $27,178	-1,007 Reduced 0.32%	315,022 $6.24 Million
Q1 2021 May 17, 2021	BUY	$18.57 - $25.68 $275,820 - $381,425	14,853 Added 4.93%	316,029 $7.35 Million
Q4 2020 Feb 12, 2021	SELL	$15.26 - $28.61 $174,681 - $327,498	-11,447 Reduced 3.66%	301,176 $6.26 Million
Q3 2020 Nov 16, 2020	BUY	$20.58 - $28.96 $762,756 - $1.07 Million	37,063 Added 13.45%	312,623 $6.77 Million
Q2 2020 Aug 14, 2020	SELL	$11.15 - $24.64 $368,897 - $815,214	-33,085 Reduced 10.72%	275,560 $6.5 Million
Q1 2020 May 15, 2020	SELL	$8.75 - $16.3 $114,660 - $213,595	-13,104 Reduced 4.07%	308,645 $3.64 Million
Q4 2019 Feb 14, 2020	BUY	$7.95 - $11.84 $29,526 - $43,973	3,714 Added 1.17%	321,749 $3.41 Million
Q3 2019 Nov 14, 2019	SELL	$10.82 - $14.25 $48,960 - $64,481	-4,525 Reduced 1.4%	318,035 $3.62 Million
Q2 2019 Aug 14, 2019	BUY	$7.95 - $11.25 $89,119 - $126,112	11,210 Added 3.6%	322,560 $3.63 Million
Q1 2019 May 15, 2019	BUY	$5.95 - $10.19 $35,491 - $60,783	5,965 Added 1.95%	311,350 $2.52 Million
Q4 2018 Feb 14, 2019	SELL	$5.91 - $9.29 $44,715 - $70,288	-7,566 Reduced 2.42%	305,385 $1.93 Million
Q3 2018 Nov 14, 2018	BUY	$6.4 - $9.85 $195,910 - $301,518	30,611 Added 10.84%	312,951 $3.08 Million
Q2 2018 Aug 14, 2018	BUY	$6.9 - $9.9 $129,375 - $185,625	18,750 Added 7.11%	282,340 $2.34 Million
Q1 2018 May 15, 2018	BUY	$7.2 - $10.05 $45,748 - $63,857	6,354 Added 2.47%	263,590 $1.9 Million
Q4 2017 Feb 12, 2018	SELL	$7.25 - $15.65 $735,708 - $1.59 Million	-101,477 Reduced 28.29%	257,236 $2.1 Million
Q3 2017 Nov 07, 2017	BUY	$12.0 - $15.0 $4.3 Million - $5.38 Million	358,713	358,713 $5.2 Million

Others Institutions Holding CYTK

# of Institutions

407

Shares Held

125M

Call Options Held

4.52M

Put Options Held

2.28M

View Full List

About CYTOKINETICS INC

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $5.15B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

More about CYTK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.

Account

Ameriprise Financial Inc Cytokinetics Inc Transaction History